Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC

NCT ID: NCT05400993

Last Updated: 2022-06-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 59 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-23
• Study Completion Date: 2024-05-23

Brief Summary

Neoadjuvant therapy for HR+/HER2- breast cancer is dominated by anthracycline combined with paclitaxel chemotherapy. Aggressive neoadjuvant chemotherapy can only achieve pCR in about 10% of PATIENTS with HR-positive breast cancer. The emergence of new targeted drugs brings new life and hope to HR-positive breast cancer patients.Basic studies have shown that the abnormal state of epigenetics is associated with the metastasis of drug resistance and recurrence of tumor histone deacetylase (HDAC) is an important regulator of epigenetic regulation, and drugs targeting HDAC provide a new strategy for tumor therapy. The ACE study suggests that selective HDAC inhibitor chidamide in combination with endocrine therapy significantly improves survival benefit in patients with hr-positive HER2-negative advanced breast cancer who relapsed or progressed after endocrine therapy, providing a new treatment option for these patients.In conclusion, we hypothesize that neoadjuvant therapy with chidamide combination therapy provides a better strategy for patients with HR + /HER2 - breast adenocarcinoma.

Detailed Description

A total of 59 patients with stage Ii-III HR + / HER2 - breast cancer were enrolled in a multi-center, single-arm prospective design. The main purpose of the study was to observe the efficacy and safety of chidamide combined with chemotherapy in neoadjuvant treatment of stage II-III HR + / HER2 - breast cancer Breast MRI and other imaging examinations were reviewed every 2 cycles to evaluate the efficacy. If the efficacy was accurate, surgical treatment was performed within 4 weeks after the 8th cycle of neoadjuvant therapy. If the efficacy was SD+/PD, the study would be withdrawn Within 4 weeks after surgical treatment, the resected tumor tissue and lymph nodes were histopathologically examined (including the pathology of the tumor resection margin). The pathological sections were uniformly lent to the master research unit for unified review

Conditions

Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

treatment group

Chidamide combined with EC -- T regimen was treated with 1 cycle every 21 days, followed by 4 cycles of EC followed by 4 cycles of T, a total of 8 cycles

Group Type: EXPERIMENTAL

Chidamide

Intervention Type: COMBINATION_PRODUCT

Chidamide: take orally twice a week,4 tablets/time (20mg/ time), the interval between two doses should not be less than 3 days (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), the day before chemotherapy, 30 minutes after breakfast； Chidamide: 20mg, orally, twice a week, oral for two weeks and one week, a total of 8 cycles； Epirubicin 90mg/m2 , ivgtt, d1 Cyclophosphamide 600mg/m 2, ivgtt, d1 Q3w, 4 cycle； sequential Docetaxel 100 mg/m 2, IVGtt, D1 Q3w, 4 cycle。

Interventions

Chidamide

Chidamide: take orally twice a week,4 tablets/time (20mg/ time), the interval between two doses should not be less than 3 days (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), the day before chemotherapy, 30 minutes after breakfast； Chidamide: 20mg, orally, twice a week, oral for two weeks and one week, a total of 8 cycles； Epirubicin 90mg/m2 , ivgtt, d1 Cyclophosphamide 600mg/m 2, ivgtt, d1 Q3w, 4 cycle； sequential Docetaxel 100 mg/m 2, IVGtt, D1 Q3w, 4 cycle。

Intervention Type: COMBINATION_PRODUCT

Other Intervention Names

pharmorubicin; Cyclophosphamide; Docetaxel

Eligibility Criteria

Inclusion Criteria

1. Women aged 18 years or older and 75 years or younger;

2. All patients were histopathologically confirmed to be estrogen receptor (ER) positive (& GT; 10%),HER2 receptor negative follows the 2018 ASCO-CAP HER2 negative interpretation guideline criteria;

3. Newly treated patients with stage II-III tumor staging meeting AJCC Version 8 criteria;

4. KPS score ≥70;

5. The functional level of the organ must meet the following requirements:

• Bone marrow function
• ANC ≥ 1.5×10 9 /L (growth factor not used within 14 days);
• PLT ≥ 100×10 9 /L (no corrective treatment within 7 days);
• Hb ≥ 100 g/L (no corrective treatment within 7 days);
• Liver and kidney function
• TBIL ≤1.5 x ULN;
• ALT and AST≤3×ULN;
• BUN and Cr≤1.5×ULN and creatinine clearance ≥50 mL/min (Cockcroft-Gault formula);

6. Able to undergo needle biopsy;

7. Volunteered to participate in the study, signed informed consent, had good compliance and was willing to cooperate with follow-up.

Exclusion Criteria

-

Participants are not allowed to participate in the clinical study under any of the following conditions:

1. Have received any other form of anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.);

2. Receiving any other antitumor therapy;

3. Bilateral breast cancer, inflammatory breast cancer or ocessive breast cancer;

4. Stage IV breast cancer;

5. Breast cancer without histopathological diagnosis;

6. Other malignant tumors within the past 5 years, except cured carcinoma in situ of the cervix;

7. Severe heart, liver, kidney and other important organ dysfunction;

8. Inability to swallow, chronic diarrhea and intestinal obstruction, there are many factors affecting drug taking and absorption;

9. Participated in clinical trials of other drugs within 4 weeks before enrollment;

10. Known history of allergy to the drug components of this regimen; History of immunodeficiency, including HIV positive, HCV, live active hepatitis B or other acquired or congenital immune deficiency diseases, or a history of organ transplantation;

11. History of any heart disease, including :(1) medically required or clinically significant arrhythmia; (2) myocardium infarction; (3) heart failure; (4) Any other heart disease deemed unsuitable for the study by the investigator;

12. Pregnant, lactating women, fertile women with positive baseline pregnancy test or in the entire women of reproductive age who were unwilling to use effective contraception during the trial;

13. According to the investigator's judgment, there are comorbidities (including but) that seriously endanger the patient's safety or affect the patient's ability to complete the study not limited to severe hypertension, severe diabetes, active infection, etc., which cannot be controlled by drugs);

14. A clear past history of neurological or psychiatric disorders, including epilepsy or dementia. The investigator considered the patient unsuitable for the study in any other case.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Shengjing Hospital

OTHER

Sponsor Role: lead

Responsible Party

Caigang Liu

Postdoctoral 、chief physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Caigang Liu, doctoral

Role: PRINCIPAL_INVESTIGATOR

Shengjing Hospital

Locations

Cancer Hospital affiliated to Harbin Medical University

Haerbin, Heilongjiang, China

Site Status: RECRUITING

Bethune First Hospital of Jilin University

Changchun, Jilin, China

Site Status: RECRUITING

Health Science and Technology Information Center of Liaoning Health Industry Group Co., LTD

Benxi, Liaoning, China

Site Status: RECRUITING

Affiliated Zhongshan Hospital Dalian University

Dalian, Liaoning, China

Site Status: RECRUITING

Shengjing Hospital of China Medical University

Shenyang, Liaoning, China

Site Status: RECRUITING

Liaoning Cancer Hospital

Shenyang, Liaoning, China

Site Status: RECRUITING

The First Affiliated Hospital of China Medical University

Shenyang, Liaoning, China

Site Status: RECRUITING

Countries

China

Central Contacts

Caigang Liu, doctoral

Role: CONTACT

liucg@sj-hospital.org

18940264967

Facility Contacts

Zhigao Li, professor

Role: primary

Dong Song, professor

Role: primary

Honglu Li, professor

Role: primary

Dianlong Zhang, professor

Role: primary

Cai-Gang Liu, PHD

Role: primary

liucg@sj-hospital.org

+86 18940254967

Hong Xu, Professor

Role: primary

Xinyu Zheng, professor

Role: primary

References

Xue J, Shan H, Qiu F, Niu N, Chen G, Xu Q, Gu X, Xing F, Xu Y, Zheng X, He G, Xu H, Zhang H, Song D, Han Y, Tang M, Cao S, Song Y, Zheng R, Zhao Y, Jiao G, Liu M, Liu C. Neoadjuvant chidamide combined with chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (MUKDEN 05): a multicentre, single-arm, phase 2 trial. Lancet Reg Health West Pac. 2025 Sep 27;63:101700. doi: 10.1016/j.lanwpc.2025.101700. eCollection 2025 Oct.

Reference Type: DERIVED

PMID: 41080407 (View on PubMed)

Other Identifiers

CSIIT-C25

Identifier Type: -

Identifier Source: org_study_id